Inventories

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventories

3. Inventories

Inventories consist of the following (in thousands):

	September 30, 2019		December 31, 2018
Raw materials	$	986	$	1,337
Work-in-process		1,675		1,605
Finished goods		1,031		655
Total inventory	$	3,692	$	3,597

Work-in-process and finished goods as of September 30, 2019 and December 31, 2018 include conversion costs but not insulin cost. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as the end of 2015. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value.  

The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at September 30, 2019. Inventory that was forecasted to become obsolete due to expiration is recorded in costs of goods sold in the accompanying condensed consolidated statements of operations. For the three and nine months ended September 30, 2019, there was no inventory write-off. For the three and nine months ended September 30, 2018, the Company recorded a $1.0 million and $1.8 million charge, respectively, to write-off inventory that may expire prior to being sold which was recorded as cost of goods sold.